TransMedics Group (NASDAQ:TMDX) Stock Price Expected to Rise, Oppenheimer Analyst Says

TransMedics Group (NASDAQ:TMDX) had its price target lifted by equities researchers at Oppenheimer from $130.00 to $150.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Oppenheimer’s price objective would indicate a potential upside of 6.69% from the stock’s previous close.

Other equities analysts have also issued research reports about the stock. Canaccord Genuity Group reaffirmed a “buy” rating and set a $104.00 price target on shares of TransMedics Group in a research report on Tuesday, March 11th. Piper Sandler restated an “overweight” rating and set a $145.00 price objective (up from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a report on Tuesday. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $127.33.

TransMedics Group Price Performance

TMDX stock traded down $1.36 on Tuesday, reaching $140.60. The company had a trading volume of 205,245 shares, compared to its average volume of 1,356,272. The company has a market cap of $4.76 billion, a P/E ratio of 149.71 and a beta of 2.10. The company’s fifty day moving average is $110.23 and its 200 day moving average is $82.77. TransMedics Group has a 1 year low of $55.00 and a 1 year high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.29 by $0.41. The firm had revenue of $143.54 million for the quarter, compared to analyst estimates of $123.39 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. TransMedics Group’s revenue was up 48.2% compared to the same quarter last year. During the same quarter last year, the business earned $0.35 earnings per share. On average, research analysts forecast that TransMedics Group will post 1 earnings per share for the current year.

Insider Transactions at TransMedics Group

In other news, Director Edward M. Basile sold 6,000 shares of TransMedics Group stock in a transaction that occurred on Friday, May 9th. The shares were sold at an average price of $115.63, for a total transaction of $693,780.00. Following the sale, the director now owns 732 shares in the company, valued at $84,641.16. This trade represents a 89.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Anil P. Ranganath sold 686 shares of the business’s stock in a transaction on Monday, June 9th. The stock was sold at an average price of $139.80, for a total transaction of $95,902.80. Following the completion of the transaction, the insider now owns 13,955 shares in the company, valued at $1,950,909. This represents a 4.69% decrease in their position. The disclosure for this sale can be found here. Insiders sold 12,418 shares of company stock valued at $1,512,613 over the last quarter. Company insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in TMDX. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of TransMedics Group by 244.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,113,082 shares of the company’s stock worth $209,448,000 after purchasing an additional 2,209,996 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in TransMedics Group by 20.6% during the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock valued at $34,145,000 after buying an additional 86,721 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in TransMedics Group by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company’s stock worth $1,314,000 after buying an additional 868 shares during the last quarter. Royal Bank of Canada grew its position in shares of TransMedics Group by 47.9% in the 1st quarter. Royal Bank of Canada now owns 26,582 shares of the company’s stock worth $1,788,000 after acquiring an additional 8,604 shares in the last quarter. Finally, Quarry LP increased its holdings in shares of TransMedics Group by 88.5% in the 1st quarter. Quarry LP now owns 592 shares of the company’s stock valued at $40,000 after acquiring an additional 278 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.